ANTIBODIES AND ANTIGEN BINDING PEPTIDES FOR FACTOR XIA INHIBITORS AND USES THEREOF
The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect o...
Saved in:
Main Authors | , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
14.07.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.
La présente invention concerne de nouveaux peptides de liaison à l'antigène, tels qu'un anticorps ou qu'un fragment d'anticorps, qui se lient spécifiquement à des inhibiteurs de FXIa sélectifs et/ou à des inhibiteurs doubles de FXIa, ainsi que de la kallicréine plasmatique. La présente invention concerne en outre des méthodes de réduction de l'effet antithrombotique d'inhibiteurs de FXIa par l'administration à un sujet d'une dose pharmaceutiquement efficace des peptides de liaison à l'antigène de la présente invention. De plus, la présente invention concerne des réactifs de détection et des méthodes de détection du niveau des inhibiteurs de FXIa dans un échantillon biologique. |
---|---|
AbstractList | The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.
La présente invention concerne de nouveaux peptides de liaison à l'antigène, tels qu'un anticorps ou qu'un fragment d'anticorps, qui se lient spécifiquement à des inhibiteurs de FXIa sélectifs et/ou à des inhibiteurs doubles de FXIa, ainsi que de la kallicréine plasmatique. La présente invention concerne en outre des méthodes de réduction de l'effet antithrombotique d'inhibiteurs de FXIa par l'administration à un sujet d'une dose pharmaceutiquement efficace des peptides de liaison à l'antigène de la présente invention. De plus, la présente invention concerne des réactifs de détection et des méthodes de détection du niveau des inhibiteurs de FXIa dans un échantillon biologique. |
Author | DILGER, Andrew Karl PINCKNEY, Jason Robert YAMNIUK, Aaron Paul KRYSTEK, JR SCHNEEWEIS, Lumelle AN, Yongmi RAKESTRAW, Ginger Chao SHERIFF, Steven EWING, William R TERRAGNI, Christina KISH, Kevin LUETTGEN, Joseph M |
Author_xml | – fullname: KRYSTEK, JR – fullname: AN, Yongmi – fullname: RAKESTRAW, Ginger Chao – fullname: PINCKNEY, Jason Robert – fullname: DILGER, Andrew Karl – fullname: YAMNIUK, Aaron Paul – fullname: TERRAGNI, Christina – fullname: LUETTGEN, Joseph M – fullname: SCHNEEWEIS, Lumelle – fullname: SHERIFF, Steven – fullname: KISH, Kevin – fullname: EWING, William R |
BookMark | eNrjYmDJy89L5WQIcvQL8XTyd_F0DVZw9HNRAHHdXf0UnDz9XDz93BUCXANCPF2Akm7-QQpujs4hQCrC01HB08_D08kTyINoCw0GKgnxcA1y9XfjYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx4f5GBkZGhqYGZkYmjobGxKkCAKBfMe4 |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | ANTICORPS ET PEPTIDES DE LIAISON À L'ANTIGÈNE POUR DES INHIBITEURS DU FACTEUR XIA ET LEURS UTILISATIONS |
ExternalDocumentID | WO2022150624A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_WO2022150624A13 |
IEDL.DBID | EVB |
IngestDate | Fri Aug 30 05:41:54 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_WO2022150624A13 |
Notes | Application Number: WO2022US11669 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220714&DB=EPODOC&CC=WO&NR=2022150624A1 |
ParticipantIDs | epo_espacenet_WO2022150624A1 |
PublicationCentury | 2000 |
PublicationDate | 20220714 |
PublicationDateYYYYMMDD | 2022-07-14 |
PublicationDate_xml | – month: 07 year: 2022 text: 20220714 day: 14 |
PublicationDecade | 2020 |
PublicationYear | 2022 |
RelatedCompanies | BRISTOL-MYERS SQUIBB COMPANY JANSSEN PHARMACEUTICALS, INC |
RelatedCompanies_xml | – name: JANSSEN PHARMACEUTICALS, INC – name: BRISTOL-MYERS SQUIBB COMPANY |
Score | 3.4076655 |
Snippet | The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | ANTIBODIES AND ANTIGEN BINDING PEPTIDES FOR FACTOR XIA INHIBITORS AND USES THEREOF |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220714&DB=EPODOC&locale=&CC=WO&NR=2022150624A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-LHlIDSt-I6s5U9DGmbdI1gWkanextLl4Eg3XAV_30vcdM97Sm5HAnJwS93l-QuAPeoMfRsXmi3Sz3l0sJASvstV_nzVk-rXkfPbLZP2U1G9HncGdfgYxMLY_OEftvkiIioAvFe2f16-X-IxezbytWDesemxVOc95mz9o7bbROP47Cwz7OUpZETRei3OXJoeSaZXpsG6CvtoSHtGzzw19DEpSy3lUp8DPsZjldWJ1DTZQMOo83faw04eFlfeWN1jb7VKQwDmYswNRYcCSQjhhxwSUIhmZADkvEsFwyZ6NmROIhyLMYiIEImIhRI_XYb4RZK8oQPeRqfwV3M8yhxcXKTP1lM3tLtlTyeQ71clPoCiN-baUVR7JQW1Ee7TNF5x0NrZIoqatryLqG5a6Sr3exrODKkOdT0aBPq1eeXvkFtXKlbK8QfbU-GEA |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8QNOKbosYP1CaavS0yLCw8ELNPVoVuIUN5I3QriYkZRGb8971WUJ546selTXvJr_fR3hXgHiWGzOeZNDvUEibNFKSk3TSFPW92pei2Za6zffJONKbPk_akAh-bWBidJ_RbJ0dERGWI91Kf18t_J5av31auHsQ7di2ewrTnG2vruNVS8TiG7_aCJPZjz_A8tNsMPtI0lUyvRR20lfZQybYVHoJXV8WlLLeFSngE-wnOV5THUJFFHWre5u-1OhwM11feWF2jb3UCI4enzI2VBkcc7hPV7AecuIz7jPdJEiQp85GIlh0JHS_FYsIcwnjEXIat32FjPEJJGgWjIA5P4S4MUi8ycXHTP15M3-LtnTyeQbVYFPIciN3NpaDIdkozaqNeJui8baE2MkMRNWtaF9DYNdPlbvIt1KJ0OJgOGH-5gkNFUg5OizagWn5-yWuUzKW40Qz9AeNMiQM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANTIBODIES+AND+ANTIGEN+BINDING+PEPTIDES+FOR+FACTOR+XIA+INHIBITORS+AND+USES+THEREOF&rft.inventor=KRYSTEK%2C+JR&rft.inventor=AN%2C+Yongmi&rft.inventor=RAKESTRAW%2C+Ginger+Chao&rft.inventor=PINCKNEY%2C+Jason+Robert&rft.inventor=DILGER%2C+Andrew+Karl&rft.inventor=YAMNIUK%2C+Aaron+Paul&rft.inventor=TERRAGNI%2C+Christina&rft.inventor=LUETTGEN%2C+Joseph+M&rft.inventor=SCHNEEWEIS%2C+Lumelle&rft.inventor=SHERIFF%2C+Steven&rft.inventor=KISH%2C+Kevin&rft.inventor=EWING%2C+William+R&rft.date=2022-07-14&rft.externalDBID=A1&rft.externalDocID=WO2022150624A1 |